Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$883.20 USD
-7.48 (-0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $881.43 -1.77 (-0.20%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 341 - 360 ( 590 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; Revenue Pushes Forward; Pipeline Progress Continues
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
No Surprise Here; Sarilumab CRL, But Think Easy to Overcome
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
8-K Points to Sarilumab CRL or Delay At Minimum; Investment Case Intact
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Time-Out to Adjust the Fasinumab Game Plan
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Full Dupixent Data Shine; Bring on the PDUFA Date
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CAPELLA Hits Bump; Eylea Alone Remains Strong Therapy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J